Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Press releases
Get the latest updates from Press releases directly as they happen.
Follow now 610 followers
Latest posts
Last updated 17 days ago
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026
17 days ago
Superiority data from LATA together with OPERA findings add to the clinical...
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
18 days ago
Investment further integrates company into world-class ecosystem of biomedical research, patient care...
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
19 days ago
Q2 results 2026
GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China
18 days ago
ARTEMIS-011, a phase III study conducted for China, met its primary endpoint...
ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV
19 days ago
Positive Week 48 data from the phase IIIb VOGUE study reinforce Dovato...
Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
24 days ago
Next-generation design aims to address key efficacy and tolerability challenges of treating...
ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026
25 days ago
VOGUE is the first head-to-head, randomised daily orals study comparing 2-drug regimen...
European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds
26 days ago
If approved, a single booster dose could help protect individuals who were...
GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)
29 days ago
GSK plc (LSE/NYSE: GSK) today provides an update on the CALM-1 and...
GSK completes acquisition of Nuvalent, Inc.
about 1 month ago
GSK plc today announced completion of its acquisition of Nuvalent, Inc...
Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer
about 1 month ago
Results support potential for dostarlimab to eliminate the need for chemotherapy, radiation...
GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population
about 1 month ago
ARTEMIS-008 met its primary endpoint of overall survival in advanced or relapsed...